Patients clinically diagnosed with mild cognitive impairment (MCI) or AD have been found Aβ-negative [4, 5], thus leading to a pathophysiology-based unbiased and descriptive amyloid, tau, and neurodegeneration classification [6, 7]. The gene discussed is MAPT; the disease is Alzheimer disease.